Showing results (421-430 of 567) with videos related to
Sort By:
Pageof 57
Investigational New Drugs|March 2, 2010
A phase II trial of sorafenib in first-line metastatic urothelial cancer: a study of the PMH Phase II ConsortiumSrikala S Sridhar, Eric Winquist, Andrea Eisen, et al.American Journal of Clinical Oncology|June 1, 1994
The role of steroids in the management of metastatic carcinoma to the brain. A pilot prospective trialA H Wolfson, S M Snodgrass, J G Schwade, et al.Diabetes, Obesity & Metabolism|May 15, 2023
Kidney protection with canagliflozin: A combined analysis of the randomized CANVAS program and CREDENCE trialsVikas S Sridhar, Brendon L Neuen, Robert A Fletcher, et al.BJU International|March 6, 2025
Understanding patient perspectives in the management of their muscle-invasive bladder cancerDeepro Chowdhury, Andrea B Apolo, Di Maria Jiang, et al.The Oncologist|November 7, 2015
Temsirolimus Maintenance Therapy After Docetaxel Induction in Castration-Resistant Prostate CancerUrban Emmenegger, Christopher M Booth, Scott Berry, et al.The Prostate|January 16, 2016
Study of testosterone-guided androgen deprivation therapy in management of prostate cancerSaroj Niraula, Arnoud J Templeton, Francisco E Vera-Badillo, et al.Epigenomics|July 12, 2022
A novel methylated cell-free DNA marker panel to monitor treatment response in metastatic prostate cancerMadonna R Peter, Misha Bilenky, Yuliang Shi, et al.Cancer|November 15, 1990
A phase I study of 4'-0-tetrahydropyranyladriamycin. Clinical pharmacology and pharmacokineticsK S Sridhar, T S Samy, R P Agarwal, et al.The Review of Scientific Instruments|October 1, 2024
Soft x-ray tomography on the high field spherical tokamak ST40C Colgan, H Bohlin, P F Buxton, et al.Journal of Kidney Cancer and VHL|March 7, 2024
The Survival Outcomes of the Metastatic Nonclear Cell Renal Cell Carcinoma in the Immunotherapy Era: Princess Margaret Cancer Centre ExperienceEsmail Al-Ezzi, Abhenil Mittal, Zachary W Veitch, et al.Pageof 57